Stockwinners Market Radar for July 12, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

17:40 EDT Oak Hill Advisors takes 5.08% passive stake in Quorum Health - Oak Hill Advisors disclosed a 5.08% stake in Quorum Health, which represents over 1.58M shares. The filing does not allow for activism.

16:31 EDT Peck announces satisfaction of Nasdaq listing requirements - The Peck Company announced that it received an Approval Letter from the Listing Qualifications Department of The Nasdaq Stock Market stating that the staff of Nasdaq has determined the company has satisfied all the Nasdaq listing requirements. In addition, the company's warrants have not demonstrated the minimum 400 round lot holder requirement for initial listing of its warrants set forth in Nasdaq Listing Rule 5515a4 following the completion of the company's business combination on June 20, 2019. The delist notice for the warrants provides that unless the company requests an appeal of the Staff's determination to a Nasdaq Hearings Panel, the company's warrants will be scheduled for delisting from Nasdaq and will be suspended at the opening of business on July 16, 2019, after which Nasdaq will remove the company's warrants from listing and registration on Nasdaq. Given the low number of warrant holders, a delisting of the warrants was anticipated after the business combination, and the company does not intend to file an appeal. Warrants will remain exercisable according to the terms set forth in the Warrant Agreement filed with pre-merger S-1 documents on November 23, 2015.

16:19 EDT Morgan Stanley reports 5.4% passive stake in Och-Ziff Capital - In a regulatory filing, Morgan Stanley disclosed a 5.4% stake in Och-Ziff Capital, which represents 1.1M shares. The filing does not allow for activism.

16:06 EDT YogaWorks announces delisting from Nasdaq - YogaWorks announced that the company has determined it to be in its best interests to proceed with plans to remove its common stock from listing on The NASDAQ Stock Market and will file an application on Form 25, Notification of Removal From Listing and/or Registration Under Section 12b of the Securities Exchange Act of 1934. The decision was based on the company's current financial situation, taking into account the fact that the company's common stock is held by relatively few holders and there is limited trading of the company's common stock on NASDAQ. The removal of the stock from listing on NASDAQ will become effective on Monday, July 22, 2019. The company will once again operate as a private company, as it did prior to its IPO. The company's duty to file any reports under Section 13a of the Exchange Act and the rules and regulations thereunder as a result of the security's registration under Section 12b of the Exchange Act shall be suspended upon the effective date of the delisting.

16:01 EDT TDH Holdings discloses Nasdaq delisting notice - TDH Holdings announced that on July 9, 2019 it received a Staff Delisting Determination letter from The Nasdaq Stock Market, LLC setting forth a determination to delist the Company's common shares from The Nasdaq Capital Market as a result of the Company's inability to regain compliance with the minimum bid price continued listing requirement under Listing Rule 5550(a)(2) within the time previously allotted by the Nasdaq Staff. The company was also subsequently notified of its failure to comply with the Listing Rule 5550(b) which requires a minimum of $2.5 million in stockholders' equity, $35 million in market value of listed securities, or $500,000 in net income from continuing operations for continued listing. The company intends to appeal this Determination by requesting a hearing before a Hearings Panel. A hearing request will stay the delisting of the company's securities. The hearing date will be determined by the Nasdaq Staff following the hearing request submission date. The company plans to address the ongoing non-compliance matters before the Hearings Panel. There can be no assurance that, following the hearing, the Panel will grant the company's request for additional time to regain compliance with the Nasdaq continued listing requirements.

14:18 EDT AB InBev says not proceeding at this time with IPO of Budweiser Brewing APAC - Anheuser-Busch InBev announced that it has decided that, at this time, it is not proceeding with the announced public offering of a minority stake in its Asia Pacific subsidiary, Budweiser Brewing Company APAC Limited, on the Hong Kong Stock Exchange. "The company is not proceeding with this transaction due to several factors, including the prevailing market conditions. The company will closely monitor market conditions, as it continuously evaluates its options to enhance shareholder value, optimize the business and drive long-term growth, subject to strict financial discipline," Anheuser-Busch InBev stated. In afternoon trading in New York following the announcement, AB InBev shares are down 3.5% to $86.52.

14:00 EDT Ur Energy trading resumes

13:32 EDT Energy Fuels trading halted, news pending

13:03 EDT Baker Hughes reports U.S. rig count down 5 to 958 rigs - Baker Hughes reports that the U.S. rig count is down 5 rigs from last week to 958, with oil rigs down 4 to 784, gas rigs down 2 to 172, and miscellaneous rigs up 1 to 2. The U.S. Rig Count is down 96 rigs from last year's count of 1,054, with oil rigs down 79, gas rigs down 17, and miscellaneous rigs unchanged at 2. The U.S. Offshore Rig Count is up 2 rigs to 26 and up 7 rigs year-over-year. The Canada Rig Count is down 3 rigs from last week to 117, with oil rigs up 5 to 85 and gas rigs down 8 to 32. The Canada Rig Count is down 80 rigs from last year's count of 197, with oil rigs down 54 and gas rigs down 26.

12:43 EDT Omnicell down again following GlassHouse claim of 'obfuscated' financials - Shares of Omnicell are continuing to fall after short-seller GlassHouse Research yesterday posted a report about the company on its website. "Significant declines in revenue and earnings await Omnicell as the company has obfuscated its financials by prematurely recognizing revenue in prior periods and failing to write-off legacy inventory," GlassHouse wrote. It added, "Omnicell possesses one of the worst net AR positions we have seen within a public company. Concealed long-term receivables and declining deferred revenues lead us to believe the company prematurely recognized approximately $38.3 million in sales over the LTM. The company may need to restate financials based on the magnitude of these inauspicious trends." Shares of Omnicell in afternoon trading are down 8%, or $6.20, to $68.91. Reference Link

12:01 EDT Halozyme announces Janssen's BLA submission for Darzalex - Halozyme Therapeutics, Inc. (HALO) announced that its collaborator Janssen Biotech, Inc. (JNJ) has submitted a Biologics License Application to the U.S. Food and Drug Administration for the subcutaneous delivery of DARZALEX for patients with multiple myeloma. "Janssen's BLA submission for subcutaneous DARZALEX represents an important development for our ENHANZE drug delivery technology business," said Dr. Helen Torley, president and chief executive officer. "We are delighted that an approval of the subcutaneous formulation may soon provide patients with multiple myeloma a new therapeutic option that offers the potential of DARZALEX with a shorter administration time."

12:00 EDT Innovative Industrial Properties falls -10.9% - Innovative Industrial Properties is down -10.9%, or -$14.97 to $122.65.

12:00 EDT The Buckle rises 9.5% - The Buckle is up 9.5%, or $1.64 to $18.95.

12:00 EDT Tower International rises 69.0% - Tower International is up 69.0%, or $12.60 to $30.87.

11:46 EDT Genmab announces submission of BLA for subcutaneous daratumumab - Genmab (GMXAY) announced that its licensing partner, Janssen Biotech (JNJ), has submitted a Biologics License Application to the U.S. Food and Drug Administration for the use of the subcutaneous formulation of daratumumab in multiple myeloma indications where the intravenous formulation of daratumumab is currently approved. In August 2012, Genmab granted Janssen an exclusive worldwide license to develop, manufacture and commercialize daratumumab, the company noted.

11:06 EDT Biqi International reports Nasdaq notification of listing rules non-compliance - Biqi International Holdings announced that on July 8 the company received notice from The NASDAQ Stock Market indicating that its common shares did not meet the continued listing requirement based on the closing bid price of the common shares for the preceding 30 business days. The company intends to request a hearing with a hearings panel at NASDAQ to appeal the delisting determination and to request a stay of the trading suspension pending the outcome of the hearing. In addition, the company will submit a plan of compliance to regain compliance with Nasdaq's requirements for continued listing.

09:58 EDT Fannie, Freddie fall amid new Sell ratings, administration's possible inaction - Shares of Fannie Mae (FNMA) and Freddie Mac (FMCC) are falling after Height Capital Markets analyst Ed Groshans initiated coverage of both stocks this morning with Sell ratings. The Treasury Department will release its plan for housing reform and the Federal Housing Finance Agency will issue its final capital rule over the next six months, Groshans told investors in a research note. The analyst forecasts the end of the "net worth sweep" that sends profits from the companies to the Treasury, and he expects the FHFA will end conservatorship of both. He also believes the Treasury Department will regard the companies' senior preferred shares as repaid, and that Fannie will raise $87B of new common equity while Freddie raises $52B. Separately, Bloomberg reported earlier today that the Trump administration is growing wary of taking bold steps toward freeing Fannie and Freddie from federal control before the 2020 election, according to people familiar with the matter. The administration sees political risk of potentially upending the U.S. mortgage market ahead of the election, Bloomberg said. In early trading, shares of Fannie Mae are down 8% to $2.60 and Freddie Mac is down 7% to $2.51.

09:47 EDT Innovative Industrial Properties falls -8.4% - Innovative Industrial Properties is down -8.4%, or -$11.62 to $126.00.

09:47 EDT U.S. Xpress Enterprises falls -15.7% - U.S. Xpress Enterprises is down -15.7%, or -76c to $4.09.

09:47 EDT Milacron rises 23.5% - Milacron is up 23.5%, or $3.18 to $16.71.

09:31 EDT NeuBase Therapeutics closes merger transaction with Ohr Pharmaceutical - NeuBase Therapeutics (NBSE) announced the completion of the merger between NeuBase Therapeutics, Inc. and Ohr Pharmaceutical (OHRP) and associated financings. The combined Company's common stock expects to begin trading on The Nasdaq Capital Market under the ticker symbol "NBSE" at the open of market trading on July 15, 2019. The previous ticker symbol was "OHRP. Immediately following the closing of the merger, the Company entered into a definitive purchase agreement for the sale of NeuBase common stock with Greenlight Capital (GRLE). Upon close of the private placement, Greenlight Capital will own ~9% of NeuBase common stock. The Company expects to close the private placement on or about July 15, 2019. The combined Company changed its name to "NeuBase Therapeutics, Inc." immediately following the closing of the merger. It will maintain its headquarters in Pittsburgh, PA, and its executive team, led by Dr. Dietrich Stephan, was appointed as the executive team of the Company upon the closing of the merger. In addition, the Company's board of directors comprised of experienced pharmaceutical executives, including Dr. Stephan, Dov A. Goldstein, M.D., M.B.A., Diego Miralles, M.D., Franklyn Prendergast, M.D., Ph.D. and Eric Richman, M.B.A., was also appointed upon the closing of the merger. Immediately prior to the closing of the merger, NeuBase completed a private placement financing of approximately $9M under the terms of the definitive agreements previously announced in March 2019.

09:28 EDT Extreme Networks commences cash offer to acquire Aerohive Networks - Extreme Networks (EXTR) announced that its wholly-owned subsidiary, Clover Merger Sub, is commencing a cash tender offer to purchase all outstanding shares of common stock of Aerohive Networks (HIVE) at an offer price of $4.45 per share. The tender offer is being made pursuant to an Offer to Purchase, dated July 12, and in connection with the Agreement and Plan of Merger, dated June 26, by and among Extreme, Purchaser and Aerohive, which Extreme and Aerohive previously announced on June 26.

09:21 EDT Ford says there is no change to $11B forecast in electric vehicles by 2022 - Ford (F) says Europe is moving faster in the mandate for zero emissions. Says was already working for a bespoke platform for Mustang and F-150. Says open to expanded capabilities in Volkswagen (VWAGY) partnership. Says there is no change to $11B forecast in electric vehicles by 2022. Says happy with opportunity to cooperate and also compete with Volkswagen. Comments taken from presentation on Ford and Volkswagen's global collaboration.

09:12 EDT Fly Intel: Pre-market Movers - HIGHER: Milacron (MCRN), up 21% after announcing a definitive agreement to be acquired by Hillenbrand (HI) in a cash and stock transaction valued at approximately $2B, including net debt... Hookipa Pharma (HOOK), up 29% after FDA clearance of the IND application for a clinical trial of HB-201... Snap (SNAP), up 3% after Goldman Sachs analyst Heath Terry upgraded shares to Buy from Neutral and raised his price target for the shares to $18 from $13... Stitch Fix (SFIX), up 5% after Goldman's Terry upgraded the stock to Buy from Neutral with an unchanged price target of $38... MediciNova (MNOV), up 8% after announcing its plans for a Phase 3 clinical trial of MN-166 in progressive multiple sclerosis following feedback from the FDA. LOWER: CannTrust (CTST), down 11% after Eight Capital analyst Graeme Kreindler downgraded shares to Sell from Neutral and cut his price target for the shares to C$4 from C$6. The analyst downgraded the shares to Neutral on July 8... Emcore (EMKR), down 17% after cutting Q2 guidance... Illumina (ILMN), down 14% after cutting its FY19 outlook... PNM Resources (PNM), down 3% after cutting its Q2 and FY19 EPS view... Brookfield Infrastructure (BIP), down 3% after a 11.765M share spot secondary priced at $42.50 per share.

09:04 EDT Generex completes acquisition of MediSource Partners - Generex Biotechnology announced the Company has completed the acquisition agreement to acquire assets and operations of Medisource Partners, an FDA-registered distributor of medical and surgical products including bone grafts and biologics from a range of surgical product manufacturers. Under the terms of the deal, Generex will acquire 100% of the assets of Medisource including business operations, accounts receivable and inventory, contracts, and real estate, in an all-stock transaction, effective August 1, 2019, following the close of Generex' fiscal year. As part of the deal, TravisBird, CEO of MediSource will continue to lead the MediSource operation and will join the Generex executive team focused on the sales, marketing, and distribution of surgical and biologic product lines.

09:03 EDT Fred's to close an additional 129 retail stores, hold inventory clearance sales - Fred's announced that it will close an additional 129 retail stores and hold inventory clearance sales across all stores in an effort to refocus its product mix, simplify its store portfolio and repay debt. Following the planned 129 closures, Fred's will have approximately 80 retail stores remaining, centered primarily around the Company's distribution center in Dublin, GA. Lists of stores that will be closed and that will remain open are included below. Fred's may evaluate re-launching certain closed stores in the future under a new operating model, with an updated assortment. The Company expects the proceeds from the inventory clearance sales will be used to repay outstanding indebtedness under its revolving credit agreement. All pharmacies will remain open and the Company will continue to fulfill prescriptions at its pharmacy locations, as it continues to pursue the sale of its remaining pharmacy locations and opportunities to monetize pieces of its real estate portfolio. The Company currently operates 166 pharmacies.

09:01 EDT Sonoma Pharmaceuticals regains compliance with Nasdaq rule - Sonoma Pharmaceuticals announced that it received a formal determination letter from Nasdaq notifying the company that it is now compliant with the minimum bid price requirement for continued listing on the Nasdaq Capital Market and is no longer subject to delisting at this time. As announced previously, on January 4, 2019, Sonoma received a letter from Nasdaq, indicating that it did not comply with the $1.00 minimum closing bid price requirement for its common stock for continued listing on the Nasdaq Capital Market. Nasdaq granted the company a compliance period of 180 calendar days, or until July 3, 2019, to regain compliance with the listing rule. Effective with the opening of the market on June 20, 2019, the company implemented a 1-for-9 reverse stock split. The closing bid price of the company's common stock exceeded the required $1.00 per share minimum over the subsequent 10 business days. Accordingly the company has regained compliance and the matter is now closed.

08:58 EDT Neovasc to explore HDE approval pathway, alternate trial designs for Reducer - Neovasc announced that the FDA has provided guidance to the company following its Sprint Discussion on June 26, together with the company's consultants and supporting U.S. cardiologists to review the clinical evidence collected to date for the Neovasc Reducer, to determine the most expedient pathway to potentially gaining regulatory approval in the United States and the quickest path to the U.S. market for these patients with an unmet need. In its guidance, the FDA has recommended that the company consider potential alternate approaches such as: the Humanitarian Device Exemption pathway for class IV refractory angina patients and/or alternate clinical trial designs for a broader refractory angina patient population. Based on the FDA's feedback, the company has decided to explore a two-pronged approach. First, the company will work with the FDA to pursue the option for the Reducer to be classified as a Humanitarian Use Device seeking an HDE approval pathway in order to bring this treatment option to those patients in the U.S. with the worst angina symptoms as soon as possible. Second, the company, in close consultation with the FDA and key opinion leaders, will evaluate an alternate investigational device exemption clinical trial design for class III and IV patients.

08:43 EDT Medovex announces name change to H-CYTE, new ticker symbol - Medovex (MDVX) announced that FINRA has approved the effectiveness of a change in the company's name from "Medovex Corp." to "H-CYTE, Inc." as well as a change in the Company's trading symbol from "MDVX" to the new trading symbol "HCYT". The change will become effective on the opening of trading as of Monday, July 15, 2019. In addition, a new CUSIP number has been assigned to the Company's common stock. The new CUSIP number for the Company's common stock is 404124109. In addition to the name and symbol change, the Company has launched a new corporate website and social channels for its investors and to provide educational resources for patients.

08:36 EDT Manhattan Associates, Newmine partner for retailer omnichannel solutions - Manhattan Associates announced its partnership with Newmine, a consulting and technology company focused on retail commerce optimization. The companies are working together to equip retailers with omnichannel solutions that deliver a seamless, holistic shopping experience. Newmine joins the Manhattan Value Partner program, which fosters collaborative partnerships with supply chain and logistics, inventory, and omnichannel commerce providers.

08:33 EDT Navios Maritime Containers appoints Erifili Tsironi as CFO - Navios Maritime Containers (NMCI) announced the appointment of Erifili Tsironi as CFO of Navios Containers. Tsironi previously served as co-CFO of Navios Maritime Acquisition Corporation (NNA) since December of 2018 and as CFO of Navios Maritime Midstream Partners L.P. from its inception in 2014 until December 2018. Chris Christopoulos, who previously served as CFO of Navios Containers, recently left the company.

08:24 EDT Hillenbrand, Milacron see double-digit earnings accretion in first full year - Hillenbrand (HI) and Milacron (MCRN) said the combined company is expected to generate annual revenues of approximately $3B and free cash flow of greater than $325M by 2021. The companies expect annualized cost synergies of approximately $50M within 3 years following the close.

08:18 EDT Hillenbrand to acquire Milacron in cash, stock deal valued around $2B

08:16 EDT Ford to use Volkswagen MEB EV architecture for 600,000 vehicles - Ford (F) plans to design an all-new, MEB-platform-based EV model, which starts arriving in 2023, in Koln-Merkenich, Germany. Volkswagen (VWAGY) will supply MEB parts and components as part of the collaboration. Both companies also will continue to target additional areas where they can work together on electric vehicles - a key strategic priority for both companies as they drive to accelerate the transition to sustainable and affordable mobility. The agreement with Ford is a cornerstone in Volkswagen's electric strategy, supporting the growth of the e-mobility industry and facilitating global efforts to reach the Paris 2050 Agreement.

08:16 EDT Ford, Volkswagen expand collaboration to advance autonomous driving - Ford (F) and Volkswagen (VWAGY) announced they are expanding their global alliance to include electric vehicles and will collaborate with Argo AI to introduce autonomous vehicle technology in the U.S. and Europe. The collaboration will position both companies to better serve customers while improving their competitiveness and cost and capital efficiencies. Working together with Ford and Volkswagen, Argo AI's self-driving system, or SDS, is the first with commercial deployment plans for Europe and the U.S. Argo AI's platform has the largest geographic deployment potential of any autonomous driving technology to date. Volkswagen and Ford independently will integrate Argo AI's SDS into purpose-built vehicles to support the distinct people and goods movement initiatives of both companies. Argo AI's focus remains on delivering a SAE Level 4-capable SDS to be applied for ride sharing and goods delivery services in dense urban areas. Ford and Volkswagen will have an equal stake in Argo AI, and combined, Volkswagen and Ford will own a substantial majority. The remainder will be used as an incentive pool for Argo AI employees. The full transaction is subject to regulatory approvals and closing conditions. Company leaders also announced Ford will become the first additional automaker to use Volkswagen's dedicated electric vehicle architecture and modular electric toolkit, or MEB, to deliver a high-volume zero-emission vehicle in Europe starting in 2023. Ford expects to deliver more than 600,000 European vehicles using the MEB architecture over six years, with a second all-new Ford model for European customers under discussion. This supports Ford's European strategy including commercial vehicles, crossovers and imported vehicles such as Mustang and Explorer. Volkswagen started developing its MEB architecture in 2016, investing approximately $7B in this platform. The car-maker is planning to use this platform to build approximately 15M cars for the Volkswagen Group alone in the next decade. For Ford, using Volkswagen's MEB architecture is part of its more than $11.5B investment in electric vehicles worldwide. The alliance, which covers collaborations outside of Volkswagen and Ford's joint investments in Argo AI, does not entail cross-ownership between the two companies and is independent from the investment into Argo AI. The alliance is governed by a joint committee and includes senior executives from both companies. The companies also are on track to deliver medium pickup trucks for global customers, aiming to start in 2022, followed by commercial vans.

08:03 EDT ShiftPixy announces stock repurchase program up to 10M shares - ShiftPixy announced that its Board of Directors has authorized the repurchase of up to ten million shares of its outstanding common stock over an initial period of 18 months, extendable at the Board's discretion. The stock repurchase program will be funded through the Company's existing cash.

07:44 EDT Australia suspends textured breast implants made by Allergan, J&J and others - Australia's Therapeutic Goods Administration announced the proposed suspension of textured breast implants "on the basis that it is likely that there are grounds for cancelling the entries of the products." It explained, "Based on the laboratory and statistical review, the TGA has proposed regulatory action in relation to a number of textured implants only. Those proposed regulatory actions are either a proposal to cancel or a proposal to suspend. The TGA has also imposed new conditions on the inclusion of a number of other textured implants in the Register." Allergan (AGN) and Johnson & Johnson (JNJ) are among the manufacturers on the suspended list. Reference Link

07:35 EDT EyePoint announces resignation of CFO David Price - EyePoint Pharmaceuticals disclosed last night that on July8, David Price notified the company of his decision to resign as Chief Financial Office, effective August 9, in order to accept another employment opportunity. The company expects that Price will continue to serve as CFO until after the filing of its quarterly report for the quarterly period ended June 30. It added, "Mr .Price's decision to depart from the Company does not reflect any disagreement with the Company on any matter relating to the Company's operations, policies or practices." EyePoint has initiated a search for a new CFO.

07:10 EDT Hillenbrand, Milacron deal seen delivering double-digit adjusted EPS accretion - The transaction is expected to deliver double-digit Adjusted EPS accretion in the first year following close and will immediately improve Adjusted EBITDA margin. Hillenbrand (HI) anticipates further margin improvement as the combined company leverages scale and realizes cost savings. Hillenbrand expects to generate free cash flow greater than $325M by 2021, retain its investment-grade credit rating, and deploy cash flow aligned with its capital allocation strategy, including maintaining its quarterly dividend. Hillenbrand expects to refinance Milacron's (MCRN) outstanding debt at close and reduce net leverage to below 2.75x within 12 months post-close. Milacron will benefit from the Hillenbrand Operating Model, and Hillenbrand expects to leverage Milacron's global shared services center to drive operational efficiency. The transaction is expected to generate annualized, run-rate cost synergies of approximately $50M within three years following close, primarily through reducing public company costs, realizing operating efficiencies, and capturing direct and indirect spend opportunities. The transaction is also expected to generate revenue synergies, driven by opportunities to cross-sell extruder and material handling equipment, and to leverage the combined service footprint to further penetrate the product aftermarket. These efficiencies will be driven across the combined organization through utilizing the HOM, while maintaining a commitment to serving customers with excellence and innovation.

07:06 EDT Hillenbrand to acquire Milacron in cash, stock transaction valued at about $2B - Hillenbrand (HI) and Milacron Holdings (MCRN) announced that they have entered into a definitive agreement under which Hillenbrand will acquire Milacron in a cash and stock transaction valued at approximately $2B, including net debt of approximately $686M as of March 31. Under the terms of the agreement, which has been unanimously approved by the Boards of Directors of both companies, Milacron stockholders will receive $11.80 in cash and a fixed exchange ratio of 0.1612 shares of Hillenbrand common stock for each share of Milacron common stock they own. Based on Hillenbrand's closing stock price on July 11, the last trading day prior to the announcement, the implied cash and stock consideration to be received by Milacron stockholders is $18.07 per share, representing a premium of approximately 34% to Milacron's closing stock price on July 11, and a premium of approximately 38% to Milacron's 30-day volume-weighted average price as of the close on July 11. Upon closing, Hillenbrand shareholders will own approximately 84% of the combined company, and Milacron stockholders will own approximately 16%. The transaction, which is expected to close in the first calendar quarter of 2020, is subject to customary closing conditions and regulatory approvals, including the approval of stockholders of Milacron. Hillenbrand intends to fund the cash portion of the transaction through debt financing and has secured a committed bridge financing facility led by J.P. Morgan.

07:04 EDT Hillenbrand to acquire Milacron in cash, stock transaction valued at about $2B

06:50 EDT Eli Lilly announces presentation of post-hoc analyses from Emgality studies - Eli Lilly announced the presentation of post-hoc analyses showing improvements in daily functioning and reductions in disability in patients with chronic and episodic migraine treated with Emgality compared to placebo. The analyses are based on data from three double-blind, placebo-controlled, Phase 3 pivotal studies of Emgality in chronic and episodic migraine. The data will be presented at the American Headache Society, or AHS. Greater and statistically significant proportions of patients treated with Emgality showed reductions in disability due to migraine, as measured by the Migraine Disability Assessment, or MIDAS, when compared to placebo. The MIDAS questionnaire measures headache-related disability as lost time due to headache from paid work or school, household work and nonwork activities. The MIDAS disability categories correspond to different levels of limitation and medical need. Among patients in the chronic migraine pivotal study REGAIN, a statistically significant increase of 46.2% was seen in the proportion of patients with "little/no disability" after three months of treatment with Emgality compared to placebo, regardless of baseline disability. In the pooled analysis of the pivotal studies for episodic migraine EVOLVE-1 and EVOLVE-2, patients with "moderate to very severe disability" at baseline were 66.1% more likely to shift to "little/no disability" after six months of treatment with Emgality compared with placebo, with the difference achieving statistical significance. Treatment with Emgality was associated with improvements across all seven items of the Migraine-Specific Quality of Life Questionnaire Role Function-Restrictive Domain, or MSQ-RFR). The MSQ-RFR questionnaire measures the degree to which migraine limits a person's daily social and work-related activities, including: feeling more energetic; feeling less tired for work or daily activities; concentrating better on work/daily activities; able to get more done at work and home; less difficulty performing work/daily activities; less interference in leisure activities and less interference dealing with family and friends. In the REGAIN pivotal study for chronic migraine, patient gains in daily functioning were greater among patients treated with Emgality compared to placebo, for all items of the MSQ-RFR, with most reaching statistical significance. In the pooled analysis of the pivotal studies for episodic migraine patient gains in daily functioning were statistically significantly greater among patients treated with Emgality as compared to placebo across all seven items of MSQ-RFR. Overall, the analyses showed that patients treated with Emgality for the prevention of chronic or episodic migraine showed improvements in migraine-related disability and functional gains in the performance of daily activities that are limited by migraine.

06:32 EDT SEACOR Marine Holdings COO Robert Clemons steps down - SEACOR Marine Holdings announced that Robert Clemons has stepped down as Executive Vice President and COO, effective as of July 12. Clemons joined SEACOR Marine as Executive Vice President and COO in June of 2017, and was previously the Vice President and COO of SEACOR Holdings Inc.'s Americas offshore division. Clemons will provide consulting services to the company for a period of time following his departure in order to assist the company with the transition of his duties. The company did not name a replacement to Clemons as COO and has no current plans to fill the position.

06:26 EDT Daimler AG sees Q2 Group EBIT (EUR1.6B) vs. EUR2.6B last year - Daimler AG said in a statement that it has achieved a Group EBIT for the second quarter 2019 that is significantly below market expectations. Group EBIT sums up to EUR minus 1.6 billion vs. EUR 2.6 billion last year. The following major items had an impact on EBIT: New information lead to a revised risk assessment with regard to provisions for an extended recall in Europe and Rest of World in connection with Takata airbags. Provisions had to be increased by around EUR 1.0 billion. In addition, EBIT was impacted by a reassessment made today in connection with ongoing governmental and court proceedings and measures relating to Mercedes-Benz Diesel vehicles in various regions, which lead to an increase in expected expenses by around EUR 1.6 billion. Finally, a decision by the Board of Management in the context of the product portfolio review and prioritization, which will affect earnings of the Mercedes-Benz Vans division in the second quarter 2019 by around EUR 0.5 billion.

06:11 EDT WPP to sell 60% stake in Kantar to Bain Capital - WPP said it plans to sell a 60% stake in Kantar to Bain Capital. The investment by Bain Capital Private Equity values Kantar at c.$4bn; WPP said its leverage target to be met a year ahead of plan; c.GBP 1.0bn shareholder return planned. Proceeds to WPP on completion after tax and continuing investment in Kantar expected to be c.$3.1bn , WPP said. WPP to retain c.60% of net proceeds to reduce debt to the low end of the target leverage range of 1.5 - 1.75x average net debt/EBITDA3 for 2020. Impact of proposed transaction and use of proceeds expected to be marginally dilutive to headline EPS in 2021. Completion and associated proceeds relating to no less than 86% of Kantar expected in early 2020, subject to approval by WPP shareholders and other customary regulatory and legal approvals. Mark Read, CEO, WPP, said: "Kantar is a great business and we look forward to working with Bain Capital to unlock its full potential. As a strategic partner and shareholder in Kantar, WPP will continue to benefit from its future growth while our clients continue to benefit from its services and capabilities."

06:01 EDT Uxin enters binding term sheet with Golden Pacer - Uxin announced that it has entered into a binding term sheet with Golden Pacer, a leading financial technology platform in China. Pursuant to the term sheet, Uxin will divest its loan facilitation related business to Golden Pacer in exchange for an aggregate of $100M cash and a certain number of shares of Golden Pacer. In addition, Uxin and Golden Pacer will also enter into a series of business cooperation arrangements. After the divestiture and through the business cooperation, Uxin will provide inspection and valuation services to Golden Pacer's used car financing transactions, and Golden Pacer will provide certain loan facilitation services for Uxin's online used car transactions, including providing a guarantee in the event of default. Uxin and Golden Pacer will work together with third-party financing partners to achieve that Uxin will no longer bear any guarantee liabilities or credit risks for used car loans facilitated after the transaction. The parties expect to enter into definitive transaction agreements and close the transaction as soon as practicable in the second half of 2019. The execution of the definitive transaction agreements and the closing of the transaction are subject to certain approvals and conditions.

05:28 EDT Campbell Soup signs a definitive agreement to sell Kelsen Group for $300M - Campbell Soup announced that it has signed a definitive agreement for the sale of Kelsen Group to a Ferrero affiliated company for $300M, subject to customary purchase price adjustments. Proceeds from the divestiture will allow Campbell to reduce debt. Closing is expected in Q1 of FY20.